Long-acting Recombinant Factor Ix Fc Fusion Protein (rfixfc) For Perioperative Management Of Subjects With Haemophilia B In The Phase 3 B-long Study

dc.creatorPowell J.S.
dc.creatorApte S.
dc.creatorChambost H.
dc.creatorHermans C.
dc.creatorJackson S.
dc.creatorJosephson N.C.
dc.creatorMahlangu J.N.
dc.creatorOzelo M.C.
dc.creatorPeerlinck K.
dc.creatorPasi J.
dc.creatorPerry D.
dc.creatorRagni M.V.
dc.creatorWang X.
dc.creatorJiang H.
dc.creatorLi S.
dc.creatorCristiano L.M.
dc.creatorInnes A.
dc.creatorNugent K.
dc.creatorBrennan A.
dc.creatorLuk A.
dc.creatorAllen G.
dc.creatorPierce G.F.
dc.creatorRobinson B.
dc.date2015
dc.date2015-06-25T12:50:54Z
dc.date2015-11-26T14:58:05Z
dc.date2015-06-25T12:50:54Z
dc.date2015-11-26T14:58:05Z
dc.date.accessioned2018-03-28T22:09:50Z
dc.date.available2018-03-28T22:09:50Z
dc.identifier
dc.identifierBritish Journal Of Haematology. Blackwell Publishing Ltd, v. 168, n. 1, p. 124 - 134, 2015.
dc.identifier71048
dc.identifier10.1111/bjh.13112
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84916232822&partnerID=40&md5=c1d3d7985e89f168ddcdac50d46ace93
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/85187
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/85187
dc.identifier2-s2.0-84916232822
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1255788
dc.descriptionIn the phase 3 B-LONG (Recombinant Factor IX Fc Fusion Protein [rFIXFc] in Subjects With Haemophilia B) study, rFIXFc demonstrated a prolonged half-life compared with recombinant factor IX (rFIX), and safety and efficacy for prophylaxis and treatment of bleeding in subjects with moderately-severe to severe haemophilia B. In this B-LONG sub-analysis, rFIXFc was evaluated for efficacy in subjects requiring major surgery. Dosing was investigator-determined. Assessments included dosing, consumption, bleeding, transfusions and haemostatic response. A population pharmacokinetics model of rFIXFc was used to predict FIX activity. Twelve subjects underwent 14 major surgeries (including 11 orthopaedic surgeries); most subjects (11/12) received rFIXFc prophylaxis before surgery (range, ~2 weeks-12 months). Investigators/surgeons rated haemostatic responses as excellent (n = 13) or good (n = 1). In most surgeries (85·7%), haemostasis from the pre-surgical dose until the end of surgery was maintained with a single rFIXFc infusion. Blood loss was consistent with similar surgeries in subjects without haemophilia. The strong correlation (R2 = 0·9586, P < 0·001) between observed and population pharmacokinetic model-predicted FIX activity suggests surgery did not impact rFIXFc pharmacokinetics. No unique safety concerns or inhibitors were observed. In conclusion, rFIXFc was safe and efficacious, with prolonged dosing intervals and low consumption, when used perioperatively in haemophilia B. Surgery did not appear to alter rFIXFc pharmacokinetics.
dc.description168
dc.description1
dc.description124
dc.description134
dc.descriptionCollins, P.W., Moss, J., Knobe, K., Groth, A., Colberg, T., Watson, E., Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX (2012) Journal of Thrombosis and Haemostasis, 10, pp. 2305-2312
dc.descriptionDiao, L., Li, S., Ludden, T., Gobburu, J., Nestorov, I., Jiang, H., Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B (2014) Clinical Pharmacokinetics, 53, pp. 467-477
dc.descriptionHermans, C., Altisent, C., Batorova, A., Chambost, H., De Moerloose, P., Karafoulidou, A., Klamroth, R., Dolan, G., Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations (2009) Haemophilia, 15, pp. 639-658
dc.descriptionKlitgaard, T., Nielsen, T.G., Overview of the human pharmacokinetics of recombinant activated factor VII (2008) British Journal of Clinical Pharmacology, 65, pp. 3-11
dc.descriptionLongo, G., Messori, A., Morfini, M., Baudo, F., Ciavarella, N., Cinotti, S., Filimberti, E., Ferrini, P.R., Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations (1989) American Journal of Hematology, 30, pp. 140-149
dc.description(2007), https://www.hemophilia.org/sites/default/files/document/files/masac179.pdf, MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). MASAC Document #179. Accessed 8-19-2013Powell, J.S., Pasi, J., Ragni, M.V., Ozelo, M.C., Valentino, L.A., Mahlangu, J.N., Josephson, N.C., Pierce, G.F., Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B (2013) New England Journal of Medicine, 369, pp. 2313-2323
dc.descriptionPowell, J., Shapiro, A., Ragni, M., Negrier, C., Windyga, J., Ozelo, M., Pasi, J., Robinson, B., Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates (2014) British Journal of Haematology
dc.descriptionPrasad, N., Padmanabhan, V., Mullaji, A., Blood loss in total knee arthroplasty: an analysis of risk factors (2007) International Orthopaedics, 31, pp. 39-44
dc.descriptionQuon, D.V., Logan, L., Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine(R) SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis (2011) Haemophilia, 17, pp. e196-e201
dc.descriptionRagni, M.V., Pasi, K.J., White, G.C., Giangrande, P.L., Courter, S.G., Tubridy, K.L., Use of recombinant factor IX in subjects with haemophilia B undergoing surgery (2002) Haemophilia, 8, pp. 91-97
dc.descriptionRudowski, W.J., Scharf, R., Ziemski, J.M., Is major surgery in hemophiliac patients safe? (1987) World Journal of Surgery, 11, pp. 378-386
dc.descriptionSommer, J., Buyue, Y., Bardan, S., Peters, R.T., Jiang, H., Kamphaus, G.D., Gray, E., Pierce, G.F., Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity (2014) Thrombosis and Haemostasis, , [Epub ahead of print]
dc.descriptionSrivastava, A., Brewer, A.K., Mauser-Bunschoten, E.P., Key, N.S., Kitchen, S., Llinas, A., Ludlam, C.A., Street, A., Guidelines for the management of hemophilia (2013) Haemophilia, 19, pp. e1-e47
dc.descriptionWhite, G.C., Beebe, A., Nielsen, B., Recombinant factor IX (1997) Thrombosis and Haemostasis, 78, pp. 261-265
dc.descriptionWindyga, J., Rusen, L., Gruppo, R., O'Brien, A.C., Kelly, P., Roth, D.A., Arkin, S., BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study (2010) Haemophilia, 16, pp. 731-739
dc.descriptionWindyga, J., Lissitchkov, T., Stasyshyn, O., Mamonov, V., Ghandehari, H., Chapman, M., Fritsch, S., Abbuehl, B.E., Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study (2014) Haemophilia, , [Epub ahead of print]
dc.languageen
dc.publisherBlackwell Publishing Ltd
dc.relationBritish Journal of Haematology
dc.rightsfechado
dc.sourceScopus
dc.titleLong-acting Recombinant Factor Ix Fc Fusion Protein (rfixfc) For Perioperative Management Of Subjects With Haemophilia B In The Phase 3 B-long Study
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución